Evidence map›Paper›PMID 36497098›Full record

ArticleCells2022

Identification and Validation of

Zhenpeng Li, Xin Wang, Yi Yang, Fuyan Shi, Wenjing Zhang, Qinghua Wang, Suzhen Wang

Open access · goldAbstract read
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. A NovelClinical Medicine Insights. Oncology · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Zhenpeng LiSchool of Medical Laboratory, Weifang Medical University, Weifang 261053, China.
Xin WangThe Second Affiliated Hospital of Chongqing Medical University, Chongqing 400000, China.
Yi YangDepartment of Health Statistics, Key Laboratory of Medicine and Health of Shandong Province, School of Public Health, Weifang Medical University, Weifang 261053, China.ORCID 0000-0002-2470-0103
Fuyan ShiDepartment of Health Statistics, Key Laboratory of Medicine and Health of Shandong Province, School of Public Health, Weifang Medical University, Weifang 261053, China.
Wenjing ZhangDepartment of Health Statistics, Key Laboratory of Medicine and Health of Shandong Province, School of Public Health, Weifang Medical University, Weifang 261053, China.
Qinghua WangDepartment of Health Statistics, Key Laboratory of Medicine and Health of Shandong Province, School of Public Health, Weifang Medical University, Weifang 261053, China.ORCID 0000-0003-3912-3174
Suzhen WangDepartment of Health Statistics, Key Laboratory of Medicine and Health of Shandong Province, School of Public Health, Weifang Medical University, Weifang 261053, China.
Weifang Medical University · CNDalian Medical University · CN

Funding

Medicine and Health Science and Technology Development Plan Project of Shandong Province 202112050480National Natural Science Foundation of China 32000495National Natural Science Foundation of China 32200512
6 · The paper itself

Abstract

Remarkable clinical benefits in several advanced cancers are observed under the treatment of immune checkpoint inhibitor (ICI) agents. However, only a smaller proportion of patients respond to the treatments. Reelin (RELN) is frequently mutated in the cancer genome. In this study, the

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsMelanomaReelin ProteinHumansImmune Checkpoint InhibitorsMutationTumor MicroenvironmentImmune Checkpoint InhibitorsReelin ProteinRELN protein, humanimmune checkpoint inhibitormelanomamolecular determinantnon-small cell lung cancerRELN mutations

Identifiers

PMID36497098
PMCPMC9741468
OpenAlexW4311046069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.